Most cited papers from Paion (Germany)

Paion (Germany)

What are the most cited papers from Paion (Germany)?

The most cited paper from Paion (Germany) is "Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study" (Werner Hacke, Anthony J. Furlan, Yasir Al‐Rawi et al., 2008), with 574 citations. Next come "Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS)" (540) and "Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy" (320).

Published TypeFieldAccessCitations

Showing 50 of 63 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study Werner Hacke, Anthony J. Furlan, Yasir Al‐Rawi et al. · The Lancet Neurology Open access	26 Dec 2008	574
2	Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS) Anthony J. Furlan, Dirk Eyding, Gregory W. Albers et al. · Stroke Open access	31 Mar 2006	540
3	Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy Nicholas J. Pastis, Lonny B. Yarmus, Frank Schippers et al. · CHEST Journal	4 Oct 2018	320
4	A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy Keith M. Borkett, Dennis Riff, Howard I. Schwartz et al. · Anesthesia & Analgesia	12 Dec 2014	238
5	Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment Thomas Stöhr, Pieter J. Colin, Joachim Ossig et al. · British Journal of Anaesthesia Open access	8 Jul 2021	213
6	A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing Colonoscopy Mark Worthington, Laurie J. Antonik, D. Ronald Goldwater et al. · Anesthesia & Analgesia	8 Oct 2013	190
7	A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy Daniel J. Pambianco, Keith M. Borkett, Dennis Riff et al. · Gastrointestinal Endoscopy	11 Sep 2015	180
8	Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial Douglas K. Rex, Raj Bhandari, Daniel G. Lorch et al. · Digestive and Liver Disease Open access	23 Nov 2020	169
9	Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Gabriel T. Liberatore, André L. Samson, Christopher Bladin et al. · Stroke Open access	Feb 2003	142
10	Pharmacological targeting of the thrombomodulin–activated protein C pathway mitigates radiation toxicity Hartmut Geiger, Snehalata A. Pawar, Edward J. Kerschen et al. · Nature Medicine Open access	24 Jun 2012	113
11	Correlation of Vital Signs and Depth of Sedation by Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) Scale in Bronchoscopy Nicholas J. Pastis, Nathan T. Hill, Lonny B. Yarmus et al. · Journal of Bronchology & Interventional Pulmonology	8 Jul 2021	93
12	Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity José P. López‐Atalaya, Benoit Denis Roussel, Denis Levrat et al. · Journal of Cerebral Blood Flow & Metabolism Open access	12 Mar 2008	90
13	Time‐to‐Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia Lauren L. Lohmer, Frank Schippers, Karl Uwe Petersen et al. · The Journal of Clinical Pharmacology Open access	27 Jan 2020	89
14	Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury Courtney Reddrop, Randal X. Moldrich, Philip M. Beart et al. · Stroke	7 May 2005	82
15	A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice Kenichi Masui, Thomas Stöhr, Marija Pesic et al. · Journal of Anesthesia	16 Jun 2022	75
16	Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system Nora Freyer, Fanny Knöspel, Georg Damm et al. · Drug Design Development and Therapy Open access	Apr 2019	73
17	Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- d -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis Richard Macrez, Pauline Obiang, Maxime Gauberti et al. · Stroke Open access	17 Jun 2011	69
18	Androgen receptor function is modulated by the tissue-specific AR45 variant Isabelle Ahrens‐Fath, Oliver Politz, Christoph Geserick et al. · FEBS Journal Open access	16 Dec 2004	64
19	Tissue-type plasminogen activator controls neuronal death by raising surface dynamics of extrasynaptic NMDA receptors Flavie Lesept, Arnaud Chevilley, Julie Jézéquel et al. · Cell Death and Disease Open access	10 Nov 2016	61
20	Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users Frank Schippers, Marija Pesic, Rob Saunders et al. · The Journal of Clinical Pharmacology Open access	3 Jun 2020	56
21	Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial Marija Pesic, Frank Schippers, Rob Saunders et al. · European Journal of Clinical Pharmacology Open access	4 Sep 2020	50
22	Vampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): A Thrombolytic Drug Optimized by Natural Selection Wolf-Dieter D. Schleuning · Pathophysiology of Haemostasis and Thrombosis	2001	50
23	Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization Robert Kleiman, Börje Darpö, Michael D. Thorn et al. · British Journal of Clinical Pharmacology Open access	7 Mar 2020	36
24	Solulin increases clot stability in whole blood from humans and dogs with hemophilia Jonathan H. Foley, Karl‐Uwe Petersen, Catherine J. Rea et al. · Blood Open access	11 Jan 2012	33
25	Desmoteplase in acute massive pulmonary thromboembolism Peter Bramlage, Andreas Graf, Peter Lechleitner et al. · Thrombosis and Haemostasis Open access	2009	33
26	Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials Marija Pesic, Thomas Stöhr, Joachim Ossig et al. · Drugs in R&D Open access	5 Aug 2020	30
27	Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats Yu‐Mi Ryang, Jon Dang, Markus Kipp et al. · BMC Neuroscience Open access	14 Nov 2011	30
28	Impact of concurrent remifentanil on the sedative effects of remimazolam, midazolam and propofol in cynomolgus monkeys Maren S. Kops, Marija Pesic, Karl‐Uwe Petersen et al. · European Journal of Pharmacology	13 Oct 2020	29
29	Thrombomodulin‐dependent protein C activation is required for mitochondrial function and myelination in the central nervous system Jan Sebastian Wolter, Lorenz Schild, Fabian M Bock et al. · Journal of Thrombosis and Haemostasis Open access	3 Sep 2016	29
30	The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model Enming Joseph Su, Melissa Geyer, Margarethe M. Wahl et al. · Journal of Thrombosis and Haemostasis Open access	24 Mar 2011	29
31	Target-controlled Infusion of Remimazolam in Healthy Volunteers Shows Some Acute Tolerance Remco Vellinga, Jeroen V. Koomen, Douglas J. Eleveld et al. · Anesthesiology Open access	27 Oct 2023	27
32	Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue Thijs van Iersel, Heimo Stroissnig, Peter Giesen et al. · Thrombosis and Haemostasis	24 Nov 2010	27
33	Decreasing the infusion rate reduces the proarrhythmic risk of NS‐7: confirming the relevance of short‐term variability of repolarisation in predicting drug‐induced torsades de pointes Elke Detre, Morten Bækgaard Thomsen, Jet D.M. Beekman et al. · British Journal of Pharmacology Open access	21 Mar 2005	26
34	Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome Thomas Gaberel, Richard Macrez, Maxime Gauberti et al. · Neuropharmacology Open access	4 Dec 2012	23
35	Development and analysis of a remimazolam pharmacokinetics and pharmacodynamics model with proposed dosing and concentrations for anaesthesia and sedation Douglas J. Eleveld, Pieter J. Colin, Johannes P. van den Berg et al. · British Journal of Anaesthesia Open access	30 Apr 2025	22
36	A miniature pig model of pharmacological tolerance to long-term sedation with the intravenous benzodiazepines; midazolam and remimazolam Toshiro Io, Rob Saunders, Marija Pesic et al. · European Journal of Pharmacology	23 Jan 2021	22
37	Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001) Lothar Bergmann, Steiner Aamdal, Sandrine I. Marreaud et al. · European Journal of Cancer	3 Jul 2008	21
38	Efficacy of remimazolam versus midazolam for procedural sedation: post hoc integrated analyses of three phase 3 clinical trials Frank Schippers, Thomas Stöhr, Van‐Anh Dao · Endoscopy International Open Open access	Apr 2022	19
39	Thrombin-induced activation of astrocytes in mixed rat hippocampal cultures is inhibited by soluble thrombomodulin Be׳eri Niego, André L. Samson, Karl‐Uwe Petersen et al. · Brain Research	18 Jan 2011	17
40	Recombinant Thrombomodulin (Solulin) Ameliorates Early Intestinal Radiation Toxicity in a Preclinical Rat Model Rupak Pathak, Junru Wang, Sarita Garg et al. · Radiation Research Open access	26 Jul 2016	16
41	Context Sensitive Decrement Times of Remimazolam Thomas W. Schnider, Charles F. Minto · Anesthesia & Analgesia	21 Jun 2013	15
42	The Metabolism of the New Benzodiazepine Remimazolam Wolfgang A. Schmalix, Karl‐Uwe Petersen, Marija Pesic et al. · Current Drug Metabolism	Feb 2024	13
43	Influence of Remifentanil on the Pharmacokinetics and Pharmacodynamics of Remimazolam in Healthy Volunteers Remco Vellinga, Jeroen V. Koomen, Douglas J. Eleveld et al. · Anesthesiology Open access	15 Jan 2025	12
44	Novel molecular aspects of prostate carcinogenesis Hellmuth‐Alexander Meyer, Isabelle Ahrens‐Fath, Anette Sommer et al. · Biomedicine & Pharmacotherapy	19 Dec 2003	12
45	Drug-Drug Interaction Potential of Remimazolam: CYP 450, Transporters, and Protein Binding Karl‐Uwe Petersen, Wolfgang A. Schmalix, Marija Pesic et al. · Current Drug Metabolism	May 2024	11
46	Pharmacokinetics and Pharmacodynamics of Remimazolam for Procedural Sedation in Children and Adolescents Pieter J. Colin, Lynn H. Bichajian, Valentin Curt et al. · Anesthesiology Open access	12 May 2025	10
47	Angiotensin II for Catecholamine Resistant Vasodilatory Shock in Patients with Acute Kidney Injury: A Post-Hoc Analysis of the ATHOS-3 Trial Anis Chaba, Alexander Zarbock, Lui G. Forni et al. · Shock Open access	2 Oct 2024	9
48	Carboxylesterase 1-Based Drug-Drug Interaction Potential of Remimazolam: In-Vitro Studies and Literature Review Karl‐Uwe Petersen, Wolfgang A. Schmalix, Marija Pesic et al. · Current Drug Metabolism Open access	7 Aug 2024	7
49	The sedative effect of remimazolam in general anesthesia for cardiac surgery measured by Narcotrend Carmine Bevilacqua, Stefan Probst, Mariola Soehngen et al. · Journal of Cardiothoracic and Vascular Anesthesia	Jun 2015	4
50	Creating realistic human model motion by hybrid motion capturing interfaced with the digital environment Jochen Bönig, Jérôme Perret, Christian Fischer et al. Conference paper	2014	4

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.